Kiatnakin Phatra Securities (KKPS) raised its target price for Bangkok Dusit Medical Services Public Company Limited (SET: BDMS) to THB 25 from THB 23.50 after updating its discounted cash flow valuation to use 2027 as the base year. The brokerage maintained its “Buy” rating, citing an outlook for double-digit profit growth in the fourth quarter of 2026.
BDMS revenue rose 3% year-on-year in October despite a high comparison base, with revenue from Thai patients up 4% and international patients up 3%. Revenue from Middle Eastern patients fell 23%. Excluding Middle Eastern and Cambodian patients, international patient revenue would have risen 9%. Overall revenue growth accelerated to 5% YoY during November 1 – 14, led by a 7% increase at upcountry hospitals.
Revenue from insured patients rose 9% YoY in the third quarter and 6% in October, compared with average growth of 2% in the first half of 2026. Management credited a dedicated team that works with insurers to keep patients within the BDMS network when their policies do not cover the full cost of treatment. One option is to refer patients to mid-tier hospitals within the group.
KKPS said growth in revenue from Thai and insured patients in October and early November, despite a 41% year-on-year decline in influenza cases, pointed to higher treatment intensity rather than flu outbreaks as a driver of growth.
The brokerage also highlighted WellEra as a potential catalyst. The project has begun pre-sales, with bookings exceeding management’s expectations. BDMS plans to hold roadshows for international customers.
KKPS expects organic growth and a favorable comparison with the fourth quarter of 2025, when BDMS recorded THB 400 million in one-off expenses, to support its profit forecast. The brokerage noted that BDMS trades at 19 times estimated 2027 earnings, against a regional peer average of 33 times.





